Clinical Trial Update: An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 open-label study evaluating patiromer in participants on hemodialysis; terminated with posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperkalemia

Drugs mentioned

• Patiromer (patiromer)

Snippet

Sponsor: Relypsa, Inc. | Conditions: Hyperkalemia | Phase 2 | Status: TERMINATED | Results posted: 2015-12-15